<DOC>
	<DOCNO>NCT00749190</DOCNO>
	<brief_summary>The objective current study investigate efficacy , safety pharmacokinetics five dos BI 10773 compare placebo give 12 week add-on therapy go metformin therapy patient T2DM insufficient glycemic control . In addition , open-label treatment arm sitagliptin ( JanuviaTM ) add-on therapy metformin .</brief_summary>
	<brief_title>BI 10773 add-on Metformin Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1 . Male female patient diagnosis type 2 diabetes mellitus previously treat metformin alone metformin one oral antidiabetic drug 2 . Stable metformin therapy least 1500 mg/day , less maximum tolerate dose . 3 . HbA1c screen 6.5 % 9.0 % patient metformin one antidiabetic drug , HbA1c &gt; 7.0 % 10 % patient metformin 4 . HbA1c &gt; 7.0 % 10.0 % Visit 2 ( Start Runin ) 5 . Age &gt; =18 &lt; 80years 6 . Body Mass Index ( BMI ) &lt; =40 kg/m2 7 . Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation 1 . Myocardial infarction , stroke transient ischemic attack ( TIA ) within 6 month prior inform consent 2 . Impaired hepatic function 3 . Renal insufficiency impair renal function 4 . Diseases central nervous system psychiatric disorder clinically relevant neurological disorder may interfere participation trial 5 . Chronic clinically relevant acute infection 6 . Current chronic urogenital tract infection 7 . History clinically relevant allergy/hypersensitivity 8 . Treatment glitazones ( e.g. , rosiglitazone , pioglitazone ) , glucagonlike peptide ( GLP1 ) analogue , insulin within 3 month prior inform consent 9 . Treatment antiobesity drug within 3 month prior inform consent 10 . Treatment systemic steroid change dosage thyroid hormone within 6 week prior inform consent 11 . Alcohol abuse drug abuse 12 . Treatment investigational drug within 2 month prior inform consent 13 . Women childbearing potential nursing pregnant , practice acceptable method birth control , plan continue use method throughout study agree periodic pregnancy test participation trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>